Louisiana State Employees Retirement System Makes New $3.33 Million Investment in Jazz Pharmaceuticals PLC $JAZZ

Louisiana State Employees Retirement System purchased a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 17,600 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,327,000.

Other institutional investors have also modified their holdings of the company. Hilltop National Bank acquired a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $36,000. LRI Investments LLC acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $38,000. Leonteq Securities AG acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $50,000. GoalVest Advisory LLC bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $51,000. Finally, Danske Bank A S acquired a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $40,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $230.02 on Friday. The firm has a market capitalization of $14.45 billion, a price-to-earnings ratio of -11,495.25, a price-to-earnings-growth ratio of 0.20 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. Jazz Pharmaceuticals PLC has a one year low of $105.00 and a one year high of $243.32. The stock’s fifty day moving average is $224.42 and its 200-day moving average is $192.63.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The business had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post 22.09 EPS for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Rick E. Winningham sold 2,741 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $241.57, for a total transaction of $662,143.37. Following the completion of the transaction, the director owned 9,567 shares of the company’s stock, valued at $2,311,100.19. This trade represents a 22.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the transaction, the director directly owned 384,682 shares in the company, valued at approximately $73,281,921. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 13,098 shares of company stock valued at $2,832,086. 4.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on JAZZ shares. Robert W. Baird set a $252.00 price target on Jazz Pharmaceuticals in a report on Wednesday, May 6th. Royal Bank Of Canada increased their target price on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. TD Cowen raised their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Raymond James Financial reissued an “outperform” rating and set a $239.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Finally, Morgan Stanley restated an “overweight” rating and set a $245.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Sixteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $246.06.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.